title: Mometasone furoate nasal spray reduces the ocular symptoms of seasonal allergic rhinitis.
abstract: BACKGROUND
  Mometasone furoate nasal spray (MFNS), a potent intranasal corticosteroid with proved efficacy in relieving nasal allergic rhinitis symptoms, has demonstrated effectiveness in improving ocular symptoms associated with seasonal allergic rhinitis (SAR) in retrospective analyses.
  
  
  OBJECTIVE
  We sought to evaluate prospectively the efficacy of MFNS in reducing total ocular symptom scores (TOSSs) and individual ocular symptoms in subjects with SAR.
  
  
  METHODS
  Subjects 12 years or older (n = 429) with moderate-to-severe baseline symptoms were randomized to MFNS, 200 microg once daily, or placebo in this 15-day, double-blind, parallel-group study. Subjects evaluated morning instantaneous TOSSs and daily reflective TOSSs, total nasal symptom scores (TNSSs; both instantaneous TNSSs and reflective TNSSs, respectively), and individual ocular and nasal symptoms. Mean changes from baseline averaged over days 2 to 15 (instantaneous) and days 1 to 15 (reflective) were calculated. Quality of life was assessed by using the Rhinoconjunctivitis Quality of Life Questionnaire.
  
  
  RESULTS
  MFNS treatment yielded significant reductions from baseline versus placebo in instantaneous TOSSs (-0.34, P = .026, coprimary end point), instantaneous TNSSs (-0.88, P < .001, coprimary end point), reflective TOSSs (-0.44, P = .005), and reflective TNSSs (-1.06, P < .001). Significant decreases in all individual reflective ocular symptoms and instantaneous eye itching/burning and eye watering/tearing were observed for MFNS versus placebo (P < .05). Numeric improvements in instantaneous eye redness were seen but did not reach statistical significance. Improvements in Rhinoconjunctivitis Quality of Life Questionnaire total scores and individual symptom domains were achieved with MFNS treatment versus placebo (P < .001). MFNS was well tolerated.
  
  
  CONCLUSIONS
  This prospective study demonstrates that MFNS significantly reduces ocular symptoms in subjects with SAR.
authors.affiliation: Allergy Associates Medical Group, San Diego, Calif., USA. prenner@aaamg.com
authors.forename: Bruce M
authors.initials: BM
authors.lastname: Prenner
authors.forename: Bobby Q
authors.initials: BQ
authors.lastname: Lanier
authors.forename: David I
authors.initials: DI
authors.lastname: Bernstein
authors.forename: Tulin
authors.initials: T
authors.lastname: Shekar
authors.forename: Ariel
authors.initials: A
authors.lastname: Teper
mesh_terms: D000281:Administration, Intranasal; D000328:Adult; D000336:Aerosols / Q000008:administration & dosage* / Q000009:adverse effects; D018926:Anti-Allergic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D004311:Double-Blind Method; D005260:Female; D006261:Headache / Q000209:etiology; D006801:Humans; D008297:Male; D008875:Middle Aged; D000068656:Mometasone Furoate; D015508:Nasal Obstruction / Q000188:drug therapy; D011244:Pregnadienediols / Q000008:administration & dosage* / Q000009:adverse effects; D011537:Pruritus / Q000188:drug therapy; D011788:Quality of Life; D012189:Retrospective Studies; D006255:Rhinitis, Allergic, Seasonal / Q000188:drug therapy* / Q000503:physiopathology; D013666:Tears
chemical_list: D000336:Aerosols; D018926:Anti-Allergic Agents; D011244:Pregnadienediols; D000068656:Mometasone Furoate